PTC Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders on June 12, 2019. The final results for the votes regarding each proposal are set forth below.

The stockholders of the Company elected three Class III directors, each to hold office until the Company’s 2022 annual meeting of stockholders or until his or her successor has been duly elected and qualified, as follows:

The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019 was ratified by the Company’s stockholders with 51,489,402 votes “For,” 123,577 votes “Against,” and 102,304 votes “Abstained.”

The non-binding advisory proposal on named executive officer compensation was approved by the Company’s stockholders with 47,844,878 votes “For,” 577,120 votes “Against,” 169,479 votes “Abstained,” and 3,123,806 broker non-votes.

About PTC THERAPEUTICS, INC. (NASDAQ:PTCT)

PTC Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule therapeutics that focus on post-transcriptional control processes. The Company’s lead product, Translarna (ataluren), is used for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients with age of over five years and older. Its programs include Translarna for nonsense mutation cystic fibrosis (nmCF), Translarna for mucopolysaccharidosis type I caused by nonsense mutation (nmMPS I), Translarna for nonsense mutation aniridia, Translarna for nonsense mutation Dravet syndrome/CDKL5, Spinal muscular atrophy (SMA) in collaboration with Spinal Muscular Atrophy Foundation (SMA Foundation) and F. Hoffman-La Roche Ltd and Hoffman- La Roche Inc. (collectively Roche), and Cancer stem cell program (PTC596). It has two compounds in clinical development within the SMA program: RG7800 and RG7916.